GlassScriptPhysician profile
Gopal Govindarajan
NPI 1124015987
$6,700.76
in general payments reported to CMS, 2019-2025
27 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $247 · 2021: $3,868 · 2022: $573 · 2023: $658 · 2024: $541 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $3,000.00 | 2021 | |
| Glaxosmithkline, LLC. | $529.86 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $523.63 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $357.51 | 2021-2025 | |
| Pfizer INC. | $235.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.42 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $214.02 | 2021-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $200.28 | 2024 | Inpefa |
| Novo Nordisk INC | $177.94 | 2021-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $172.74 | 2020-2024 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $153.25 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $141.99 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $139.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.44 | 2021-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $92.82 | 2024 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $83.02 | 2023 | |
| Amgen INC. | $78.46 | 2025 | Repatha, Repatha |
| Alexion Pharmaceuticals, INC. | $61.67 | 2021 | |
| Edwards Lifesciences Corporation | $28.24 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Gilead Sciences, INC. | $26.50 | 2023 | |
| Boston Scientific Corporation | $24.81 | 2021 | |
| Cvrx, INC. | $24.10 | 2022 | |
| Shield Therapeutics INC | $20.67 | 2024 | |
| Janssen Biotech, INC. | $20.20 | 2024 | Xarelto |
| Medtronic Vascular, INC. | $19.40 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $18.32 | 2023 | Arcalyst |
| Baxter Healthcare | $17.91 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopal Govindarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.